Immunovant Inc (IMVT)

NASD · Healthcare · Biotechnology · USA

Immunovant Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Immunovant is a clinical-stage immunology company developing IMVT-1402, an FcRn inhibitor for autoimmune diseases driven by pathogenic IgG antibodies. The company is conducting clinical trials in six indications including Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, Sjögren's disease, and cutaneous lupus erythematosus.

From its FY2026 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Immunovant Inc stock.

Our verdict on IMVT

Not valued: We cannot value this company yet.

ETFs with the most weight in IMVT

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than IMVT in Biotechnology

129 more in this industry show a wider margin of safety.

Is IMVT undervalued or overvalued?

We do not publish a verdict on IMVT yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of IMVT?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.